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Objectives: Since 1992, the Food and Drugs Administration (FDA) accelerated 
approval pathway has enabled market entry of drugs for serious conditions based 
on a surrogate endpoint that is likely to predict clinical benefit with confirma-
tory trials to be completed post-approval. However, five drugs have since been 
withdrawn or severely restricted following accelerated approval due to lack of effi-
cacy (bevacizumab, [indication: breast cancer; withdrawn 2011; approved 2009], 
amifostine [indication: renal toxicity; withdrawn: 2006; approved: 1996], gefitinib 
[withdrawn: 2005; approved: 2003), safety concerns (gemtuzumab, withdrawn 2010; 
approved 2000), or lack of confirmatory trial data (celecoxib, indication: Familial 
Adenop Polymatosis [FAP], withdrawn: 2011, approved 1999), leading to criticisms 
that this pathway allows drugs to enter the market prior to their efficacy and safety 
being adequately demonstrated. This research aims to evaluate these criticisms 
by comparing how the drugs were assessed by the European Medicines Agency 
(EMA). MethOds: EMA and FDA evaluations of these drugs were sourced; the 
approval decision, date, and rationale were compared, alongside any post-approval 
restrictions/withdrawals. Results: EMA appraisal information was publically avail-
able for bevacizumab, gefitinib, gemtuzumab, and celecoxib. Gemtuzumab (EMA 
refused, 2008) and gefitinib (EMA submission withdrawn 2005 after failing Phase III 
trial) were not granted EMA licences in the FDA-approved indications. In contrast, 
bevacizumab (2007) and celecoxib (2003) were EMA-approved with the same data 
package used to gain approval by the FDA. In 2011, celecoxib was withdrawn for 
FAP in both Europe and US due to lack of confirmatory trial data. However, bevaci-
zumab was EMA approved a year earlier than the FDA and has not been withdrawn 
by the EMA in this indication. cOnclusiOns: FDA accelerated approval pathway 
criticism due to post-approval drug withdrawals may be overstated, as the EMA 
approved two of the five drugs subsequently withdrawn by the FDA, one of which 
the EMA has not withdrawn.
PHP23
Estimation of CHangE in PrEsCriPtion Drug ExPEnDiturEs on tHE 
rEfErEnCE PriCing systEm in soutH KorEa
Heo J.H.1, Rascati K.L.2, Lee E.K.3
1University of Texas at Austin, Austin, TX, USA, 2The University of Texas at Austin, Austin, TX, 
USA, 3Sungkyunkwan University, Suwon-si, Gyeonggi-do, South Korea
Objectives: A reference pricing system is a policy strategy that sets a reim-
bursement level or reference price for a group of therapeutically interchange-
able drugs, i.e. the reference group. A patient is responsible for any difference 
between the reference price and the price of a more costly drug. The purpose of 
this study was to estimate future prescription drug expenditures after implemen-
tation of the reference pricing system in South Korea. MethOds: Korean national 
health insurance data collected for January, April, July, and October in 2011 were 
obtained from the Health Insurance Review and Assessment Service. All medica-
tions were included to estimate drug expenditures, except patented drugs and 
orphan drugs. A reference group was defined as the category including drugs with 
same ingredient or same therapeutic class. Possible scenarios after the introduc-
tion of the reference pricing system, such as a copay deduction program for only 
drugs below the reference price by the government, price lowering by companies 
and changes in prescribing patterns, were included in the model. Results: A 
base-line copay rate of 20.4% was calculated. When a reference price was set 
at the average price of drugs in the reference group, patient co-payment rates 
were estimated to increase to 23.9%. However, when we assumed that companies 
reduce the price by 5% and prescribers changed 10% of prescriptions to avoid 
patients paying additional co-payments, co-payment rates were estimated to be 
22.9%. In addition, the copay deduction could help decrease co-payment rates to 
19.6%. cOnclusiOns: Reference pricing system can contribute to a reduction 
in prescription medication expenditures for third-party payers. The co-payment 
for patients could be increased by moving additional financial burden from the 
insurer to patients. However, an increase in co-payment rates could be limited and 
total drug expenditures could be reduced by copay discounts, medication price 
reductions or prescribing changes.
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Objectives: This study evaluates pharmaceutical companies pricing strategies 
after generic entry into the New Zealand market in the period 2007-2012, and its 
effects on drug utilization and expenditures. MethOds: Market data derived from 
IMSHealth. Data include active ingredient, route, dosage form, strength, brand/
generic status, prescription drug (Rx)/over-the-counter status, date of market entry, 
ex-manufacturer standard unit sales, and ex-manufacturer NZ dollars sales. NZ$ 
were adjusted to 2012 using the NZ consumer price index. Study sample includes the 
37 products of the top 125 products by sales in the period 2007-2012 that experienced 
generic entry during the study period. Results: Sales of products in the top 125 by 
sales amounted NZ$3.1 billion; 46.6% of the overall NZ market. Brands accounted for 
95.8% of the expenditures. The average ex-manufacturer price per standard unit was 
NZ$55.9 (95%CI: NZ$43.8-67.9) for Rx, and NZ$ 685.8 for therapeutic biologics (95%CI: 
NZ$482.3-889.2). The median price at generic entry date was 27.4% of the median 
brand price. The median price at generic entry date of study sample was NS$1.18 
per unit for brands and NS$0.32 for generics. In 2012, the median price per unit was 
down to NZ$0.83 and NZ$0.22 for brands and generics, respectively. Standard unit 
sales increased on average 14% (95% CI 7%-21%) after first year of generic entry. 
Several brand products (clopidogrel, letrozole, omeprazole, pantoprazole) were dis-
continued after generic entry. cOnclusiOns: Generic entry resulted in an average 
30% reduction in the average drug price. Brand companies either reduced the brand 
price to match generic prices, or maintained the brand price at levels immediately 
before generic market entry. The first strategy resulted in the brand keeping large 
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Objectives: To reveal the main causes of non-compliance for technology incorpo-
ration requests into the Brazilian Public Health System (SUS) for the period of 2012 
and 2013. MethOds: This was a descriptive cross-sectional study. The analysis was 
performed using the database of National Committee for Technology Incorporation 
(CONITEC) submitted applications for incorporation in the years 2012 and 2013. The 
CONITEC, which belongs to the Ministry of Health of Brazil, is responsible for the 
incorporation, exclusion or alteration of new medicines, procedures and products 
on the public health system. The presentation of economic evaluation by applicants 
(economic study and a budget impact analysis) is necessary to enable the analysis of 
the proposed requirements. Results: Out of the 142 external (outside the Ministry 
of Health) requests submitted for analysis, 56 (39%) were non-compliant, 50 (89%) 
of them were due to problems in the economic evaluation. Out of the economi-
cally non-compliant, 16 (32%) presented problems in the economic study only and 
32 (64%) of them presented problems in both items. The main problems observed 
were not submitting an economic study, not submitting the economic model used 
in the study, and presenting an economic study using a different perspective than 
the one of SUS. cOnclusiOns: The high percentage of non-compliance due to the 
economic evaluation points out the difficulty faced in completing these studies. It 
is important to invest in initiatives, human resources, training and spreading of 
economic evaluation knowledge which enables clarifying the required criteria for 
applying for an incorporation request.
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Objectives: Ten years after completion of the Human Genome Project, progress 
towards making personalized medicine a reality has been slower than expected. 
This paper seeks to identify how evidence has been generated by critically evaluat-
ing successful MDx case studies, and, to the extent possible, identify any lessons 
from them. MethOds: A literature review identified nine examples of success 
where diagnostic tests are bringing personalized medicine into clinical practice 
with positive health and economic impact for patients, health care systems, and 
manufacturers. Results: Each case demonstrates that a companion MDx can 
provide information to patients and health care providers; allow for a targeting of 
treatments or other interventions to a subset of the population despite differences 
in whether they are prognostic, predictive, or used for monitoring; offer the potential 
for the health system to deliver more health gain. cOnclusiOns: There is a diver-
sity of approaches in developing MDx and the range of challenges posed both by the 
science and in acceptance and use. Moreover, because of the great potential value of 
personalized medicine for patients and health systems alike, there is a compelling 
rationale that both payers and the public sector should help fund research on the 
clinical effectiveness of MDx.
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Objectives: In spite of the globalization of the pharmaceutical industry, differences 
exist in the number and characteristics of the pharmaceutical products available 
in each country. This study compared the pharmaceutical products approved in 
the US and registered in Peru as of December, 2013, and assessed differences in 
approvals of chemical entities, therapeutic biologics and orphan drugs, and generic 
entry. MethOds: Information about pharmaceutical products approved in the US 
and Peru was obtained from the US Food and Drug Administration (FDA), and the 
General Directory of Medicines, Supplies, and Drugs of Peru (DIGEMID), respec-
tively. Descriptive statistics and chi-square tests were performed in the analysis. 
Significant level was set at 0.05. Results: A total of 2,409 approved pharmaceutical 
products were listed by the FDA as of December, 2013 of which 763 (31.7%) were 
also registered by DIGEMID, including 39.1% of generic multisource products and 
25.1% of brand single source products. A total of 112 biologic products were listed by 
the FDA and 64 (57.1%) were also registered in Peru. There were 368 products with 
orphan indications approved by the FDA and 112 (30.4%) were also registered in Peru. 
Generic competition was available for 46.8% of the products approved by the FDA 
and 57.8% of the products approved by DIGEMID (p< 0.001). cOnclusiOns: Peru 
has substantially less pharmaceutical products approved than the US, especially 
for brand products without generic competition and orphan drugs. The highest 
percentage of products approved in both countries corresponded to therapeutic bio-
logics. Part of the differences in drug approvals can be explained by variations in the 
epidemiological profile of both countries. The relatively small size of the Peruvian 
pharmaceutical market and limited purchasing power may result in reduced incen-
tives for pharmaceutical companies to register new molecular entities and products 
for orphan diseases in Peru.
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label comparators requested) between 2008 and 2013 for not being cost-effective, 
thereby indirectly recommending the off-label alternative. cOnclusiOns: NICE 
have rejected new interventions in favour of off-label comparators. However, there 
may be a recent shift towards more manufacturers choosing not to compare to the 
requested off-label comparator and for NICE to accept this decision.
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Objectives: Market access for innovative new technologies can be complex and 
time consuming. As cost-containment pressures intensify, evidentiary hurdles to 
justify new point-of-care (POC) tests continue to grow. Decentralized health care 
decision making also can be a significant hurdle. This study aimed to characterize 
the process and identify challenges for health technology assessment (HTA), pric-
ing, reimbursement, and market access for a new POC test in the United States (US) 
and Canada. MethOds: We conducted desktop research of published literature, 
HTA reports, and third-party websites to identify the critical path and data most 
valuable to reimbursement decision making. We also conducted qualitative one-
on-one interviews with payer decision makers in the US (15 payers) and Canada (1 
payer advisor and 2 laboratory directors). Results: Reimbursement is critical to 
rapid adoption of new technologies. There are multiple appropriate access pathways 
for various theatres of care (e.g., outpatient office/clinic, inpatient, emergency), all 
with varying requirements and value drivers. Payment for new diagnostic tests 
typically is handled regionally or locally; treating physicians and medical societies 
can influence these budget decisions. Test reimbursement processes may differ for 
inpatient versus outpatient use. Currently, the evidence hurdle for a POC test is not 
as high as for prescription medicines. cOnclusiOns: Market access for a POC test 
is variable; adequate data to meet decision makers’ needs is not well understood. 
No roadmap exists for navigation of the critical path for POC tests, and evidence 
requirements in the US and Canada are not well established. Access for a POC test 
will be complex; regardless of pathway, decisions regarding reimbursement and 
adoption of new technology are diverse and dispersed across and within countries 
with varying levels of required evidence.
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Objectives: External reference pricing (ERP) is one of the most common cost-
containment tools used to reduce prices for in-patent pharmaceuticals in European 
Union Member States. The objective of this project was to assess the real life impact 
of ERP in Europe using a simulation model. MethOds: A simulation model (devel-
oped for the EU Commission) was built to simulate the evolution of drug price over 
time through the ERP process. Real-life cases of medicinal products were randomly 
selected from medicines approved via the European Medicines Agency centralised 
procedure between 2000 and 2012 and including off-patent/in-patent drugs, cheap/
medium-priced/expensive drugs, and orphan/non orphan drugs. IMS price database 
was selected as source of information, covering 26 European countries and includ-
ing 12 years history price data. Model outcomes were compared to actual recorded 
prices and interpretation of outcomes was enlightened with the French and Scottish 
Health Technology Assessment (HTA) reviews. Results: Fifty three medicines were 
selected for the analysis of real-cases. The following trends were observed: 1) When 
a product was initially recognized as an innovative product by HTA, actual price of 
this product appeared to consistently achieve a higher price than the ERP model 
price; 2) Actual price of the product tended to become lower than ERP model price 
over time when a product had extension of indications over time and generated 
high revenue; 3) Low GDP countries tended to be the last to achieve drug entry, 
suggesting the use of launch sequence strategy from the marketing authorization 
holder. cOnclusiOns: The ERP model seemed to well predict actual prices. ERP 
seems to be modulated by drug innovation as acknowledged by HTA. More research 
is needed to understand the role of launch sequence for price optimization.
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Objectives: “Device Lag” is one of the most imminent issues for medical device 
industry to focus for the coming years. In order to effectively approach this struc-
tured problem, the recognition of related facts and figures are the key factors. 
The purpose of this research is to provide the analysis of predictability difference 
among medical device categories in US and Japan and its background.  MethOds: 
Based on the database of US PMA approved medical devices from 2004 to 2013 and 
new medical devices approved in Japan since April 2007, which point was 3 years 
from the establishment of PMDA (Pharmaceutical and Medical Device Agency) in 
Japan, 260 devices in US and 101 devices in Japan were identified for the analysis 
of predictability. Statistical values related to regulatory review period were com-
pared between US and Japan and also among the device categories. Results: By 
two-sided paired t test New Medical Device regulatory review period (15 devices 
approved in both countries) had no significant difference (P value>0.9).  Among the 
product categories in the United States, for the identification of which the advisory 
committee classification was used, the standard deviation of FDA review time was 
the smallest in the fields of Radiology (202.5 days) followed by Microbiology (211.0 
days) and Pathology (246.6 days) and the largest in the fields of General & Plastic 
market unit and NZ$ shares, and a decline in total NZ$ sales. The second strategy 
resulted in a rapid decline of brand product market unit and NZ$ market shares.
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Objectives: To evaluate the impacts of two pharmaceutical cost containment 
policies-financial incentive for physicians to reduce their prescription drug expen-
ditures and lump-sum drug price cut implemented in Oct. 2010 and Apr. 2012 respec-
tively- on prescription drug expenditures from 2009 to 2012 in the national health 
insurance system of Korea. MethOds: Claims data for outpatient services in a 
random sample of 1,625 clinics were drawn from the national health insurance 
database between 2009 and 2012. Segmented regression analyses of interrupted time 
series were used to evaluate changes in prescription drug expenditures and non-
drug expenditures per claim for selected common diseases – gastric ulcer & gastro-
oesophageal reflux disease (adults), acute upper respiratory infection (URI) (adults/
children), and acute lower respiratory infection (LRI) (adults/children). Results: 
Prescription drug expenditures increased immediately after the implementation 
of financial incentive program in gastric ulcer & gastro-oesophageal reflux disease 
and LRI in adults. Monthly trends of prescription drug expenditures significantly 
decreased after the policy in all diseases analyzed. Lump-sum drug price cut sud-
denly dropped prescription drug expenditures. However, monthly trends of drug 
expenditures significantly increased after that. Neither of the two policies has 
changed the level or trend of non-drug expenditures. cOnclusiOns: Financial 
incentive to physicians for reducing prescription drug costs was associated with 
decreased trends of prescription drug expenditures without increasing non-drug 
expenditures. Drug price cut led to instant reductions of prescription drug expen-
ditures, however, it increased the monthly trends of prescription drug expenditures 
after the sudden reduction. The differential effects of two policies provide implica-
tions for pharmaceutical cost containment strategies in health insurance system.
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Objectives: Drug shortages are a complex and global phenomenon. When a drug 
cannot be delivered at the moment of patient demand, every stakeholder in the 
health care system is affected. MethOds: This study aims to investigate the char-
acteristics, clinical impact, financial impact and management of drug shortages in 
European hospital pharmacies. An online survey was designed based on literature 
and interviews with Belgian pharmacists. The online survey was sent to subscribers 
of Hospital Pharmacy Europe between June and September 2013. Descriptive statis-
tics of the respondent’s answers were calculated. Results: One hundred sixty-one 
respondents were considered in this study. Results show variations between drug 
shortage characteristics in European regions and countries. Besides manufacturing 
problems, a role for European and national policy measures related to the mar-
ket access and trade of pharmaceuticals, such as tendering and parallel trade, are 
discussed as a root cause for drug shortages. Further, respondents indicate drug 
shortages in Europe are associated with clinical risks for patients such as medication 
errors, a financial burden on hospitals and increased workload for the hospital phar-
macy. The median number of hours spent to the management of drug shortages by 
hospital pharmacists was estimated to be 12.85hours/week. While pharmaceutical 
companies and wholesalers already assist the hospital pharmacy in the manage-
ment of shortages, a role is still reserved for the government. cOnclusiOns: This 
study showed drug shortages have a significant effect on hospitals, their personnel 
and patients. Mandatory notification in advance and centralized information is 
proposed to reduce workload for hospital pharmacists. Further, this will allow early 
anticipation of drug shortages and facilitates mitigation of the clinical impact on 
patients. Monitoring of the effect of policy measures on the availability of drugs is 
required to reveal and tackle the root causes behind drug shortages.
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Objectives: NICE in the UK has a remit to compare new interventions to estab-
lished care, which could include off-label medication. The objective was to update 
the assessment of how frequently NICE request off-label comparators and the sub-
sequent implications. MethOds: All NICE single technology appraisal (STA) scopes 
from 01/01/08 to 18/12/13 were reviewed. Off-label comparators were identified 
as those that were being used outside their licence according to the Electronic 
Medicines Compendium. In cases where off-label comparators were requested 
in the scope, the manufacturer’s submission, the Evidence Review Group report 
and the final NICE guidance were reviewed to ascertain the outcome of this 
request. Results: Of 111 completed STAs reviewed, the scopes of 31 (27.9%) 
requested comparison to at least one off-label comparator; the proportion has been 
relatively stable over time. Since the previous analysis at the end of 2012, there 
has been a slight shift to more manufacturers not comparing to the requested 
off-label comparator (51.6% at end 2013 versus 45.8% at end 2012; driven by 80% of 
2013 cases). NICE accepted the decision to not compare to the off-label agent in a 
much higher proportion of appraisals at the end of 2013 (81.3%) versus at the end 
of 2012 (63.6%). Two appraisals where NICE had originally rejected the new technol-
ogy in favour of an off-label comparator had been re-appraised and NICE reversed 
their decision and now recommend the new interventions (TA274 and TA301). 
Overall however, NICE have rejected 8 new interventions (25.8% of scopes with off-
